The first two authors contributed equally to this work It is commonly accepted from gene expression studies that the CB2 receptor is expressed by most cell types of the rodent and human immune system. However, the exact identity of cells expressing CB2 receptor protein in human blood or the abundance of receptors expressed by each immune subset is not well characterised. We conducted a detailed analysis of CB2 protein levels expressed by bloodderived immune cells from healthy human donors. Flow-cytometry was conducted using 4 commercially available anti-CB2 polyclonal antibodies in conjunction with a selection ofimmune cell specific markers. Across multiple healthy subjects we observed that NK cells, B-Iymphocytes and monocytes expressed a higher level of CB2 receptor than CD4+or CD8+T-Iymphocytes. Neutrophils also expressed a low level of CB2 receptor. NK cells had the greatest variation in CB2 expression levels, whereas for each of the other cell types CB2 levels were relatively similar between subjects. In contrast to other methods, the high sensitivity of flow-cytometry revealed that CB2 receptors are present on resting T-Iymphocytes at low abundance in some healthy subjects. These data provide the first detailed analysis of CB2 protein levels in blood leukocyte subsets from healthy donors and identifies the cell types which could be targeted with CB2-mimetic drugs in humans.
by each immune cell-type in human blood from healthy individuals to establish "basal" receptor levels in steady-state cells. This is an important requisite for future therapeutic CB2 strategies for humans.
The ability to analyse CB2 receptor expression at the protein level, has been hampered greatly by the lack of reliable commercially available antibodies. Therefore, most evidence for expression has relied upon the detection of CB2 mRNA (1, 7) with some studies using pharmacological evidence to support the presence of functional cannabinoid receptors (9, (14) (15) (16) (17) (18) . The mRNA for CB2 has been detected under various conditions in most immune cell types (7, (19) (20) . In the human immune system, B-lymphocytes and natural killer cells express the highest levels of CB2 mRNA, followed by monocytes. However, the relative level of CB2 protein in immune cells of healthy individuals has not been studied. Recently, several CB2 antibodies have been validated for detection of endogenous CB2 receptors in human tissues (7, 15, (21) (22) (23) (24) (25) . The objective of this study is to conduct a detailed comparative analysis of CB2 protein expression by each leukocyte subset in human blood from healthy individuals using flowcytometry. This will enable us to identify which human immune cells are capable of responding to locally released endocannabinoid ligands as well as cannabinoid-mimetic drugs. With a comprehensive understanding of CB2 expression, we can begin to determine the functions within each leukocytesubset and identify potential cannabinoid targets for the regulation of inflammatory responses in humans (11) (12) (25) (26) .
MATERIALS AND METHODS

Collection of human blood and preparation of cell cultures
Blood samples (15-20 mL) were collected from 8 healthy volunteers after informed consent under ethical approval from the University of Auckland human ethics committee (reference #2009-101). Blood was collected into EDTA-coated collection tubes and maintained at room temperature. For the neutrophil and whole-blood inclusion experiments direct immunofluorescence staining was conducted following the BD Lyse/No-Wash protocol (BD-Biosciences) using freshly collected blood. Peripheral blood mononuclear cells (PBMC) were prepared from whole-blood following gradient centrifugation through Histopaque 1077 (Sigma) using Leucosep tubes (27) . Following centrifugation at 800 x g the PBMC were recovered from the plasma layer and washed gently several times with RPMl media. Single cell suspensions were cryopreserved in 50% RPMI 1640, 40% FBS and 10% dimethyl sulfoxide using a protocol which does not affect cell surface phenotype (28) .
CE2 antibody panel
The CB2 antibodies used in this study were purchased from Affinity Bioreagents (ABR, Cat # PAll-744), Sigma (Cat # CI483), Abeam (Cat # ab3561), and Santa Cruz (Cat # sc-l 0071). These antibodies recognise epitopes located within the N-terminus of the CB2 protein. The ABR CB2 antibody was raised against the first 33 amino acids of human CB2, whereas the Abeam and Sigma CB2 antibodies were raised to residues 1-32 of rat CB2 and cross-react with human CB2. The immunogen for the Santa Cruz CB2 antibody is described as "mapping near to the N-terminus of the human CB2 receptor". The exact epitope sequence has not been declared by Santa Cruz.
Flow cytometry analysis
All flow-cytometry experiments were conducted using a FACSCalibur flow-cytometer (Becton-Dickenson) using standardised techniques (28) (29) [HBI5e] (Serotec, Oxford, United Kingdom) were used at previously optimised titrations. The concentration of each CB2 antibody was optimised by testing a range of titres from 1:100 to 1:1000, with a 1:400 dilution providing an optimal signal for each CB2 antibody tested (data not shown). Single cell suspensions were incubated simultaneously with anti-CB2 and the respective fluorophore conjugated primary antibodies on ice for 45 minutes. Unbound primary antibody was removed by washing with PBS supplemented with 1% foetal bovine serum. Anti-CB2 antibodies were then detected with goat anti-rabbit Alexa 488 or 647 (Invitrogen, Carlsbad, CA) (detection of ABR, Sigma and Abeam CB2) or sheep anti-goat Alexa 488 (Invitrogen) (detection of Santa Cruz CB2). Secondary antibodies were diluted 1:500 with PBS supplemented with 1% foetal bovine serum and incubated for 20 minutes with cells on ice. The activation status of monocytes was monitored using CD83, and CD69 was used for B-lymphocytes and T-lymphocytes (30) (31) . For all experiments a minimum of 3 donors were used and for each donor the experiment was repeat at least three times.
Two-colour live-cell immunocytochemistry
Live cell immunofluorescence was conducted by staining the cells using the method described above for flow-cytometry. Briefly, PBMC were probed with antibodies detecting CD3 [UCHTl], CDI4 [MEM-18] (Serotec) and CB2 (ABR), which were subsequently detected with the corresponding isotype-specific goat antimouse or goat anti-rabbit secondary antibodies conjugated to Alexa 488 or 555 (Invitrogen). Cells were maintained at 4T. Immediately prior to imaging, the cells were placed on glass slides, cover slipped and allowed to settle for approximately 2 minutes. Images were acquired using a Leica DMR microscope equipped with epi fluorescent filters for UV, FITC and TRITC. Images were acquired using a 63x HCX PL Apo objective and a Nikon Digital Sight DS-UI camera, and processed using EclipseNet (Nikon) image acquisition software and Photoshop (Adobe Systems, Mountain View, CA).
RESULTS
Comparison ofthe stainingpattern ofCB2 antibodies in major leukocytes subsets
Four commercially available antibodies directed at the N-terminus of CB2 were compared for the detection of cell-surface CB2 receptors ( Fig.  1 ). PBMC were stained to distinguish between B-lymphocytes (CD20+), CD4+ T-lymphocytes (CD4+/CD3+), CD8+ T-lymphocytes (CD8+/CD3+), monocytes (CDI4+) and natural killer cells [NK, (CD3neg/CD8mid/CDI6+/CD56+)] ( Fig. 1 , left hand panels). The CB2 antibody comparison demonstrated that the Santa Cruz CB2 antibody was not able to detect cell surface CB2 in any of the leukocyte subsets. The Sigma, ABR and Abeam CB2 antibody staining indicated that some T-lymphocytes (CD4+ and CD8+) had low levels of cell surface CB2. This is a significant observation as other studies employing histology and western blotting have reported that steady-state T-lymphocytes (21, 32) do not express CB2. We found that CB2 protein expression by NK cells, B-lymphocytes and monocytes was considerably higher than that for T-lymphocytes. The Sigma, Abeam and ABR CB2-antibodies produced a relatively similar staining pattern for each cell type. However, the Sigma antibody appeared to strongly bind to a subset ofB-lymphocytes and NK cells; this intense level of staining was not observed with the other CB2 antibodies tested.
Whilst validating the staining profile of a subsequent batch of the Abeam CB2 antibody (same Cat#, different lots#) we noted a substantial difference in the intensity of the staining (Fig. 2) . The staining profile of batch I was compared with batch 2 using previously optimised titre conditions determined for batch I (1:400 dilution). Fig. 2 shows an example of the direct comparison of the two Abeam batches used at 1:400 dilution on the same PBMC preparation in the same experiment. This revealed that the profile was similar however, that the staining from Abeam batch I was an order of magnitude stronger than that of the newer lot (batch 2) of Abeam CB2 antibody. This is depicted in the figure by the difference in the rightward shift for CB2 staining (black-line in the flow-chart) for each leukocyte subset.
Detailed characterisation of CB2 expression by human leukocyte subsets
Flow cytometry was conducted using PBMC from 5 healthy volunteers to determine the relative level of CB2 expression by CD8+ and CD4+ Tlymphocytes, B-lymphocytes, monocytes and NKcells. All ofthese experiments were conducted using the CB2 antibody obtained from ABR ( Fig. 3) .
A significant observation from this study is that some steady-state T-lymphocytes express a low level of CB2 receptor protein. The level of CB2 expressed by T-lymphocytes was higher in some subjects than others. This is demonstrated most clearly between subject 2 [modest 5-fold change in mean fluorescent intensity (MFI)] and subjects 3 and 4 (CB2 levels were negligible), which may reflect the natural variation in the expression of CB2 by different individuals (Fig. 3a ). Most B-lymphocytes, NK cells and monocytes expressed moderate to high levels of cell surface CB2. Interestingly, the highest levels of cell surface CB2 were detected on NK cells for subjects 2 and 4, whereas monocytes had the highest level of CB2 for subjects 1 and 2. The variation in CB2 expression for each cell type between subjects is shown in Fig. 3b . CB2 expression by NK cells showed the greatest degree of variation across subjects ranging from a 5-fold to 25-fold shift for subjects 3 and 4, respectively (Fig. 3b ). Again, this may represent an example of normal variation which warrants further investigation. Such variation makes ranking expression levels inappropriate as ] CDm,m.""",,, l i r;:::] 1 CD' '·,mp"oc,'" ĨC~~:j] ĨLAJ ]NKcel l s .. our data suggest that for some subjects NK cells have the highest level whereas for other individuals monocytes express the highest. The low level of CD69 (B and T lymphocytes) and CD83 (monocytes) expression (see Fig. I ; data not shown in subsequent figures) demonstrates that the CB2 expression profile measured in this study relates specifically to immune cells under steady state conditions.
Fig. 3. Characterisation of CB2-expression by the major leukocyte subsets in PBMC from multiple healthy subjects. a) The black line on the histograms show the relative expression levels of CB2 (ABR antibody) by CD4 and CD8 Tlymphocytes, Bslymphocytes, monocytes and NK cells. The control stain for each leukocyte population is indicated by the shaded grey area. CB2 expression was measured in five healthy subjects. b) The scatter plot shows the fold change in the geometric mean fluorescent intensity (MFI) across subjects for each cell type; CD8' T-lymphocytes (CD8), CD4+ Tlymphocytes (CD4), B-lymphocytes (B), NK-cells (NK) and monocytes (M). (c-j) Dualfluorescence immunocytochemistry ofcell surface CB2 expression by monocytes and T-lymphocytes. Cell surface labelling ofthe CB2 receptor with the ABR CB2 antibody shows expression by (c-d) monocytes (CD14+) and (e-j) T-lymphocytes (CD3'). For clarity the arrows highlight the position ofthe T-lymphocyte in panel
Live cell imaging of cell-surface eB2 receptor expression
Flow cytometry results were verified by immunocytochemistry using live cell imaging on PBMC preparations. Dual immunofluorescence was conducted on PBMC cultures with the ABR CB2 antibody (I :400) and markers for T-Iymphocytes (CD3) and monocytes (CD14), which represent 
. Expression ofCB2 by neutrophils and whole-bloodfrom multiple healthy subjects. Flow cytometry was conducted using whole blood fro m healthy subjects. a) Neutrophils were identified using their fo rward and side scatter profile and cell surf ace expression of CD16 (33). CB2 expression was assessed using the ABR CB2 antibody, shown by the black line with the grey area indicating the control stain. Data are f rom three subj ects repeated three time independently, data shown is fro m one representative experiment. b) The major leukocyt e subsets account f or the maj ority of CB2-positive cells present in human blood. Flow-cyt ometry was conducted using whole-blood from healthy donors stained with a cocktail of F1TC-conjugated antibodies (CD3/CD 14/CD16/CD19/CD56) to simultaneously label lymphocytes, NK cells, monocytes, and neutrophils. The absence of CB2+cells fro m the upper-left quadrant reveals that these leukocyte populations account fo r the maj ority of the CB2-receptor expressing cells in human blood. These data are representative ofthree independent experiments.
examples of CB2 Io \\ and CB2 high expressmg cells, respectively. The immunocytochemistry demonstrated that the monocyte CB2 levels were sufficiently abundant to visualise by standard immunocytochemistry, however the low level of CB2 expressed by T-lymphocytes was not ( Fig. 3 c-f).
Expression o/CE2 receptor by human neutrophils
The expression ofCB2 by human neutrophils was investigated using whole-blood from health y donors (PBMC preparations do not contain neutrophils due to differential gradient separation). Importantly, the blood was proce ssed immediately to minimise the risk of acti vating the cells. Flow cytometry was conducted using the ABR CB2 antibody and neutrophils were ident ified on the basis of their forward/side scatter profile and surface expression of CD16 (33) (Fig. 4a ) . Steady state human neutrophils have moderate cell surface CB2 expression ( Fig.  4a) . As a final step in the characterisation, whole blood was stained with markers inclusive for T-lymphocytes (CD3 +), monocytes (CDI4+), Blymphocytes (CD 19+), neutrophils (CD 16+), and NK cells (CD56+) to determine whether there were any leukoc yte populations expressing CB2 not accounted for (Fig. 4b ) . The absence of a CB2 + population in the upper left-quadrant of the flow-chart in Fig. 4b indicates that there were no additional populations expressing CB2 that were not already accounted for.
DISCUSSION
We conducted a deta iled study to precisely define the relati ve expre ssion of CB2 by blood-borne immune cells from healthy human volunteers. This is important as it will reveal those cells that are potentially regulated by the endocannabinoid system and those that represent direct targets for therapeutic CB2-ligands.
The lack of specificity of GPCR receptor antibodies (34) including CBl receptors (35) is an ongoing challenge for researchers. We therefore tested four different commercially available CB2 antibody preparations (from ABR, Abeam, Sigma and Santa Cruz) on blood from healthy volunteers to determine CB2 in living immune cells, The antibodies (all recognise N-terminal epitopes of CB2) were chosen primarily for their potential to detect cell-surface CB2 in living immune cells. In addition, the ABR CB2 (21, 23) and Abeam CB2 (36) antibodies have been used successfully to detect endogenous CB2 receptors on human tissue sections using immunohistochemistry.
Initial comparative experiments were conducted using all four CB2 antibodies to assess the expression patterns in PBMCs. The ABR, Abeam and Sigma antibodies produced very similar CB2 detection patterns in PBMC preparations, with moderate to high levels of CB2 detected in monocytes, Blymphocytes, and NK cells in contrast to CD4+ and CD8+ T-lymphocytes that had very low levels of CB2. These initial comparative studies were particularly reassuring in that the staining pattern of these three CB2 antibodies provided good agreement. Furthermore, the striking difference in binding between different leukocyte subsets, for example the T-lymphocytes (CB2 1ow ) and NK cells (CB2 high ) , provided confidence that the CB2 antibodies were binding genuine CB2 receptors. In contrast, the Santa Cruz CB2 antibody failed to detect cell-surface CB2 in any of the PBMC leukocytes, including Blymphocytes or NK cells which have been reported to express the highest levels of CB2 mRNA (7) . While precise details are not available, the epitope used to raise this CB2 antibody is located within amino acids 10-60. If the IgG binds amino acids 33-60 which comprise the first transmembrane domain and intracellular loop, then this antibody is unlikely to be suitable for live-labelling procedures. We have used this antibody successfully for histological localisation of CB2 in ischemic rodent brain (25) , implying suitability under certain detection conditions. This finding stresses the importance of full disclosure by commercial providers of the epitope sequence to which the antibody is raised.
On closer scrutiny ofthe staining profile obtained with the Sigma CB2 antibody (Fig. 1 ), we noted that some NK cells and B-lymphocytes stained intensely (beyond the 4 th log) which was not consistent with a normal profile of expression. This high intensity signal is more indicative of non-specific binding and was not observed in the other cell types or for the ABR or Abeam CB2 antibodies. Because of this unusual staining pattern it was decided to exclude the Sigma CB2 antibody from further experiments in this study. We also noted that although a second batch of the CB2 antibody purchased from Abeam produced a similar profile of staining to our original batch the staining intensity was approximately an order of magnitude less. This demonstrates the importance of batch consistency, in particular for human studies or pathological tissues (clinical) where quantitative assessments are being made. Consistent results were obtained using the ABR antibody hence this antibody was used for further analysis.
One of the most striking observations in this study is that CB2 receptor protein was expressed by all of the major leukocyte subsets present in human blood (distinguishable with current cell surface markers). In all 5 of our subjects the lowest level of CB2 expression was by the T-lymphocytes. We have demonstrated for the first time that steadystate T-lymphocytes in some healthy individuals express low levels of CB2 receptor protein. Our data is consistent with there being detectible CB2 mRNA in both CD4+ and CD8+ T-lymphocytes (7) and advances the findings of others (32) , where CB2 expression was detected in activated T-lymphocytes, but not steady state cells. This difference may simply be an issue of greater sensitivity provided by flow-cytometry over other methods (32) . Further investigation is required to determine whether the low level of CB2 expression we observed in steady state T-lymphocytes is functionally relevant and whether it is sufficient to confer cannabinoid control. Of the other major leukocyte subsets present in healthy human blood (i.e. B-Iymphocytes, NK cells, monocytes and neutrophils) all had abundant levels of CB2 receptor protein. These data indicate that all of the major human leukocyte subsets express CB2 protein and are therefore likely regulated by the endocannabinoid system. Furthermore, it is important to recognise that each of these cell types is therefore a potential target for CB2-mimetic drugs.
Earlier studies assessing CB2 expression in humans have primarily focused on lymph nodes; lymph nodes are a crucial part of the immune system where immune responses are initiated. Using immunohistochemistry Galiegue and colleagues detected CB2 receptor in human tonsils (7) , noting CB2-immunoreactivity in B-lymphocyte rich areas. Similarly, another study detected CB2 expression by B-lymphocytes in both healthy and tumourinfiltrated lymph node sections (21) , however, interestingly, T-lymphocytes lacked CB2 expression. In contrast, in T-non-Hodgkin's lymphoma lymph nodes T-lymphocytes did express CB2 (21) . Although some paralells can be drawn between cells which express CB2 in the lymph node and blood i.e. B-lymphocytes, the expression levels of CB2 by immune cells in lymph nodes under steady state or reactive conditions may not be representative of immune cells in blood, highlighting the importance of assessing CB2 expression in each individual tissue. This study represents the first comprehensive analysis detailing CB2 protein expression by each of the major human leukocyte subsets in whole blood and PBMC from healthy individuals.
